ASH 2024 | The combination of olutasidenib and azacitidine in IDH1-mutated AML

The olutasidenib study included a variety of cohorts, some single agent and some in combination. So in this particular abstract, we focused on those that received the combination. That included some patients with refractory relapse disease, some previously untreated. It also included some patients that were already receiving olutasidenib and if they lost their response we were able to add azacitidine. So it’s a little bit of a diverse group of patients and these are all individually relatively small cohorts but we wanted to see the potential efficacy and definitely the safety of the combination because we all know that as effective as this drug and this class of drugs is we want to use them in combination with other agents. So in terms of the efficacy, we saw a very good response rate, particularly of course in the patients that had not received prior therapy or who had not received prior azacitidine or prior IDH inhibitors. The responses were really very good. Patients who had already been exposed to those drugs, the response rate was lower, but still we did see some patients who had a good response to the combination. In terms of the safety, the combination is very safe. We, of course, see some of the differentiation syndrome, probably less so when you use it in combination than when we use the olutasidenib as a single agent. There is no increase in any of the other adverse events. There’s no increase, for example, in elevation of transaminases. Still a very manageable combination. So this analysis of these different cohorts provides evidence that this combination is valuable. Of course, there needs to be additional studies so that this combination can become standard, but this sets the foundation for that next step and make them available.

This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.